Scinai Immunotherapeutics (SCNI) Net Cash Flow (2018 - 2026)

Scinai Immunotherapeutics has disclosed Net Cash Flow across 9 years of filings, most recently posting -$2.6 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 67.6% year-over-year to -$2.6 million; the TTM figure through Jun 2026 stood at -$3.9 million (down 4.71% YoY), while the FY2025 annual figure was -$285000.0, up 90.19% from the prior year.
• Net Cash Flow came in at -$2.6 million for Q2 2026 at Scinai Immunotherapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.3 million in Q1 2026 to a low of -$3.6 million in Q2 2022.
• Average Net Cash Flow over 5 years is -$1.6 million, with a median of -$1.7 million recorded in 2022.
• Year-over-year, Net Cash Flow tumbled 2286.36% in 2025 and jumped 223.05% in 2026.
• Over 5 years, Net Cash Flow stood at -$863000.0 in 2022, then plunged by 69.06% to -$1.5 million in 2023, then soared by 163.33% to $924000.0 in 2024, then slumped by 266.34% to -$1.5 million in 2025, then plunged by 67.6% to -$2.6 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$2.6 million in Q2 2026, $1.3 million in Q1 2026, and -$1.5 million in Q2 2025.